サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1565127

クロストリジウム・ディフィシル治療の世界市場

Clostridium Difficile Treatment

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
クロストリジウム・ディフィシル治療の世界市場
出版日: 2024年10月04日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

クロストリジウム・ディフィシル治療の世界市場は2030年までに20億米ドルに達する見込み

2023年に14億米ドルと推定されるクロストリジウム・ディフィシル治療の世界市場は、分析期間2023-2030年にCAGR 5.2%で成長し、2030年には20億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるメトロニダゾールは、CAGR 5.9%を記録し、分析期間終了時には9億1,560万米ドルに達すると予測されます。バンコマイシン分野の成長率は、分析期間中CAGR 4.7%と推定されます。

米国市場は3億8,380万米ドルと推定され、中国はCAGR 4.8％で成長すると予測される

米国のクロストリジウム・ディフィシル治療市場は、2023年に3億8,380万米ドルと推定されます。世界第2位の経済大国である中国は、2023-2030年のCAGRを4.8%として、2030年には3億1,300万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.9%と4.0%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界のクロストリジウム・ディフィシル治療市場- 主要動向と促進要因のまとめ

クロストリジウム・ディフィシル治療がヘルスケアで注目される理由とは？

クロストリジウム・ディフィシル（C. difficile）の治療は、特に病院や長期療養環境における感染症の発生率の上昇により、ヘルスケアにおいて重要な分野となっています。C. difficile感染症（CDI）は抗生物質関連下痢の主な原因であり、大腸炎や敗血症などの重篤な合併症を引き起こし、場合によっては死に至ることもあります。この細菌は、特に高齢者、免疫不全患者、長期にわたる抗生物質治療を受けている患者において深刻な課題となります。C.difficile感染症の罹患率と再発率の増加により、感染症に対処するだけでなく、この病原体に共通する問題である再発を予防する効果的な治療プロトコールにスポットライトが当てられています。その結果、感染の拡大を抑制し、リスクの高い環境における患者の転帰を改善するために、新規治療法やより包括的な治療アプローチの開発が臨床医と研究者の双方にとって優先事項となっています。

治療アプローチの進歩により、クロストリジウム・ディフィシル管理の状況はどのように変化するか？

最近のC. difficile治療における進歩は、単に感染を除去することから、腸内細菌叢を回復させ再発を予防することに重点を移しています。歴史的に、CDIの第一選択治療はメトロニダゾールやバンコマイシンのような広域抗生物質であり、これらは細菌の根絶を目的としていました。しかし、抗生物質の使用は腸内細菌叢をさらに破壊し、再発のリスクを高めるというパラドックスをもたらします。この課題に対処するため、腸内細菌のバランスを回復させることを目的とした新しい治療法が登場しました。例えばフィダキソミシンは、より標的を絞った抗生物質で、感染を効果的に治療しながら腸内細菌叢の破壊を最小限に抑えることができます。また、糞便微生物叢移植（FMT）は再発性CDIに対する有効性の高い治療法として注目されています。FMTでは、ドナーから健康な腸内細菌を患者に移植することで、微生物の多様性を回復させ、C. difficileが再び優勢になるのを防ぐ。これと並行して、ベズロトクスマブのようなモノクローナル抗体が開発され、C. difficileが産生する毒素を中和し、再発の可能性を減らしています。これらの進歩は治療成績を向上させるだけでなく、短期的な緩和よりも長期的な解決に焦点を当てた、臨床医によるC. difficile管理へのアプローチ方法を変革しています。

クロストリジウム・ディフィシルの治療において、代替療法と予防戦略はどのような役割を果たしますか？

抗生物質や新たな生物学的治療に加えて、代替療法や予防戦略がC. difficile感染症に対抗する上でますます重要な役割を果たしています。クロストリジウム・ディフィシル感染症の再発は依然として最大の課題の一つであり、そのため治療に対するより総合的なアプローチを模索する努力がなされています。例えば、プロバイオティクスは抗生物質治療中あるいは治療後に有益な腸内細菌を補充し、CDIのリスクを減少させる可能性について研究されています。プロバイオティクスの有効性に関するエビデンスはまだまちまちであるが、腸内健康を維持するための有望な補助療法です。さらに、ワクチン開発も進行中であり、C. difficile毒素に対する長期的な免疫の獲得を目的としたいくつかの候補が臨床試験中です。医療現場でも予防対策が目立つようになってきており、C. difficileの蔓延を抑えるために、適切な手指衛生、環境浄化、抗生物質管理プログラムなどの厳格な感染対策が実施されています。これらの戦略は、抗生物質の過剰使用を最小限に抑え、脆弱な患者におけるC. difficileの過剰増殖を防ぐための標的療法の使用を奨励することに重点を置いています。これらの代替療法や予防戦略が発展するにつれて、従来の治療を補完し、CDIを管理するためのより包括的なアプローチに貢献することが期待されます。

クロストリジウム・ディフィシル治療市場の主な成長促進要因は？

クロストリジウム・ディフィシル治療市場の成長の原動力となる要因はいくつかありますが、特にヘルスケア環境におけるCDIの発生率の増加と抗生物質耐性の蔓延が挙げられます。特に病院や長期介護施設で抗生物質治療を受ける患者が増えるにつれ、C. difficile感染の可能性が急増し、効果的で革新的な治療オプションに対する需要が高まっています。CDI患者の再発率が高いことも、フィダキソマイシンやベズロトクスマブのような、従来の広域抗生物質と比較してより効果的な長期的解決策を提供する標的治療の開発に拍車をかけています。さらに、糞便微生物叢移植（FMT）やマイクロバイオーム回復治療を含むマイクロバイオームベースの治療法の進歩は、CDI治療における重要な課題の1つである、将来の感染を予防するための腸内環境の回復に対処するものであるため、成長の原動力となっています。また、CDIが大きな医療負担であるとの認識が広まったことで、ワクチンや新規治療アプローチの研究開発への資金が増加し、市場をさらに押し上げています。さらに、病院におけるより厳格な感染制御の実践と抗生物質スチュワードシップ・プログラムの実施により、予防戦略と連動できる専門的治療の必要性が高まっています。最後に、CDIに罹患しやすい高齢者人口の拡大が、この層特有のニーズに対応する治療への需要を後押ししており、ヘルスケアを取り巻く環境が進化するにつれて市場が成長し続けることを確実にしています。

調査対象企業の例（注目の38社）

  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma, Inc.
  • Da Volterra
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Merck & Co., Inc.
  • MGB Biopharma
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Rebiotix, Inc.
  • Romark L.C.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Valneva SE

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP11052

Global Clostridium Difficile Treatment Market to Reach US$2.0 Billion by 2030

The global market for Clostridium Difficile Treatment estimated at US$1.4 Billion in the year 2023, is expected to reach US$2.0 Billion by 2030, growing at a CAGR of 5.2% over the analysis period 2023-2030. Metronidazole, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$915.6 Million by the end of the analysis period. Growth in the Vancomycin segment is estimated at 4.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$383.8 Million While China is Forecast to Grow at 4.8% CAGR

The Clostridium Difficile Treatment market in the U.S. is estimated at US$383.8 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$313.0 Million by the year 2030 trailing a CAGR of 4.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.9% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Clostridium Difficile Treatment Market - Key Trends and Drivers Summarized

Why Is Clostridium Difficile Treatment Becoming a Focus in Healthcare?

The treatment of Clostridium difficile (C. difficile) has become a significant area of focus in healthcare due to the rising incidence of infections, particularly in hospital and long-term care settings. C. difficile infections (CDI) are the leading cause of antibiotic-associated diarrhea and can lead to severe complications, such as colitis, sepsis, and in some cases, death. This bacterium poses a serious challenge, especially among the elderly, immunocompromised patients, and those undergoing long-term antibiotic treatment, as antibiotics often disrupt the gut microbiota, creating an environment where C. difficile can thrive. The increasing rates of CDI and recurrent infections have placed a spotlight on effective treatment protocols that not only address the infection but also prevent recurrence, which is a common issue with this pathogen. As a result, the development of novel therapies and more comprehensive treatment approaches has become a priority for both clinicians and researchers in order to curb the spread of the infection and improve patient outcomes in high-risk environments.

How Are Advancements in Treatment Approaches Changing the Landscape of Clostridium Difficile Management?

Recent advancements in C. difficile treatment have shifted the focus from merely eliminating the infection to restoring the gut microbiome and preventing recurrence. Historically, the first-line treatment for CDI involved broad-spectrum antibiotics like metronidazole or vancomycin, which were aimed at eradicating the bacterium. However, the use of antibiotics presents a paradox, as they can also further disrupt the gut microbiota, increasing the risk of recurrence, which occurs in about 20-30% of patients after their initial treatment. To address this challenge, newer therapies have emerged that aim to restore the balance of gut bacteria. Fidaxomicin, for instance, is an antibiotic with a more targeted approach, minimizing disruption to the gut microbiota while effectively treating the infection. In addition, fecal microbiota transplantation (FMT) has gained attention as a highly effective treatment for recurrent CDI. FMT involves the transfer of healthy gut bacteria from a donor to the patient, restoring microbial diversity and preventing C. difficile from re-establishing dominance. Alongside these, monoclonal antibodies like bezlotoxumab have been developed to neutralize toxins produced by C. difficile, reducing the likelihood of recurrence. These advancements are not only improving treatment outcomes but also transforming the way clinicians approach C. difficile management, focusing on long-term resolution rather than short-term relief.

What Role Do Alternative Therapies and Prevention Strategies Play in Treating Clostridium Difficile?

In addition to antibiotics and emerging biological treatments, alternative therapies and preventive strategies are playing an increasingly important role in combating C. difficile infections. The recurrence of CDI remains one of the greatest challenges, which is why efforts have been made to explore more holistic approaches to treatment. Probiotics, for example, have been investigated for their potential to replenish beneficial gut bacteria during or after antibiotic therapy, thereby reducing the risk of CDI. While evidence regarding the efficacy of probiotics is still mixed, they represent a promising adjunct therapy for maintaining gut health. Additionally, vaccine development is underway, with several candidates in clinical trials aimed at providing long-term immunity against C. difficile toxins. Preventive measures are also becoming more prominent in healthcare settings, where rigorous infection control practices, such as proper hand hygiene, environmental cleaning, and antibiotic stewardship programs, are being implemented to reduce the spread of C. difficile. These strategies focus on minimizing antibiotic overuse and encouraging the use of targeted therapies to prevent the overgrowth of C. difficile in vulnerable patients. As these alternative therapies and prevention strategies evolve, they are expected to complement traditional treatments and contribute to a more comprehensive approach to managing CDI.

What Are the Key Growth Drivers in the Clostridium Difficile Treatment Market?

The growth in the Clostridium difficile treatment market is driven by several factors, most notably the increasing incidence of CDI in healthcare settings and the rising prevalence of antibiotic resistance. As more patients undergo antibiotic treatment, particularly in hospitals and long-term care facilities, the likelihood of C. difficile infections has surged, creating a growing demand for effective and innovative treatment options. The high rate of recurrence among CDI patients has also spurred the development of more targeted therapies, such as fidaxomicin and bezlotoxumab, which offer more effective long-term solutions compared to traditional broad-spectrum antibiotics. Additionally, advancements in microbiome-based therapies, including fecal microbiota transplantation (FMT) and microbiome restoration treatments, are driving growth as they address one of the key challenges in treating CDI—restoring gut health to prevent future infections. The growing recognition of CDI as a major healthcare burden has also led to increased funding for research and development of vaccines and novel therapeutic approaches, further propelling the market forward. Moreover, the implementation of stricter infection control practices and antibiotic stewardship programs in hospitals is enhancing the need for specialized treatments that can work in conjunction with prevention strategies. Finally, the expanding elderly population, who are more susceptible to CDI, is fueling demand for treatments that cater to the unique needs of this demographic, ensuring that the market continues to grow as the healthcare landscape evolves.

Select Competitors (Total 38 Featured) -

  • Actelion Pharmaceuticals Ltd.
  • Astellas Pharma, Inc.
  • Da Volterra
  • Finch Therapeutics Group, Inc.
  • Immuron Ltd.
  • Merck & Co., Inc.
  • MGB Biopharma
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Rebiotix, Inc.
  • Romark L.C.
  • Sanofi Pasteur SA
  • Seres Therapeutics, Inc.
  • Summit Therapeutics Plc
  • Synthetic Biologics, Inc.
  • Valeant Pharmaceuticals International, Inc.
  • Valneva SE

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Clostridium Difficile Treatment - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Clostridium difficile Infections (CDI) Drives Demand for Advanced Treatment Options
    • Increased Awareness of Recurrent C. difficile Infections Propels Growth in Innovative Therapies
    • Development of Targeted Antibiotics Strengthens the Business Case for New C. difficile Treatments
    • Expanding Use of Fecal Microbiota Transplantation (FMT) as an Effective Solution for Recurrent CDI
    • Growing Focus on Microbiome-Based Therapies Expands the Addressable Market for CDI Treatment
    • Here's How Increasing Hospital-Acquired Infections Spur the Need for More Effective C. difficile Treatments
    • Increased Adoption of Monoclonal Antibodies Facilitates Market Growth
    • Advancements in Rapid Diagnostics Sustain Growth by Enabling Timely Treatment of CDI
    • Rising Incidence of Antibiotic Resistance Expands Market Potential for Non-Antibiotic CDI Treatments
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Clostridium Difficile Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Clostridium Difficile Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Clostridium Difficile Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metronidazole by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Metronidazole by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Metronidazole by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Vancomycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Vancomycin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Vancomycin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Fidaxomicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Fidaxomicin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Fidaxomicin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • JAPAN
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • CHINA
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • EUROPE
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Clostridium Difficile Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Clostridium Difficile Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • FRANCE
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • GERMANY
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Rest of Europe Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Rest of Europe 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Clostridium Difficile Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Asia-Pacific Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Asia-Pacific 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of World Historic Review for Clostridium Difficile Treatment by Segment - Metronidazole, Vancomycin and Fidaxomicin Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of World 16-Year Perspective for Clostridium Difficile Treatment by Segment - Percentage Breakdown of Value Sales for Metronidazole, Vancomycin and Fidaxomicin for the Years 2014, 2024 & 2030

IV. COMPETITION